Department of Surgery, Addis Ababa University, Addis Ababa, Ethiopia.
Urolithiasis. 2023 Jun 8;51(1):87. doi: 10.1007/s00240-023-01459-x.
Urolithiasis is the most common benign urological health condition. It has contributed sizeable burden of morbidity, disability, and medical health expenditure worldwide. There is limited high level of evidence on the efficacy and safety of treatment options of large renal stones. This network meta-analysis has examined the effectiveness and safety of various large renal stone management strategies. Systematic review and network meta-analysis (NMA) study design was employed to summarize comparative randomized controlled trials on humans with a diagnosis of renal stone larger than or equal to 2 cm in size. Our searching strategy was based on the Population, Interventions, Comparison, Outcomes, and Study (PICOS) approach. Medline via PubMed, Embase, Google scholar, SCOPUS, Science Direct, Cochrane library, Web of Science, and ClinicalTrials.gov were searched from inception to March 2023 to find eligible articles. Data extraction, screening, selection and risk of bias assessment were conducted by two independent reviewers. We found ten randomised control trials which consists 2917 patients, nine of them were labeled as low risk and one article was high risk. This network meta-analysis found that SFR was 86% (95% CI 84-88%) for Mini-PCNL, 86% (95% CI 84-88%) for standard PCNL, 79% (95% CI:73-86%) for RIRS, and 67% (95%CI:49-81 for staged URS for management of large renal stone. Overall complication rate was 32% (95% CI 27-38%) for standard PCNL, 16% (95% CI 12-21%) for Mini-PCNL, and 11% (95% CI 7-16%) for RIRS. Mini-PCNL (RR = 1.14 (95% CI 1.01-1.27) and PCNL (RR = 1.13 (95% CI 1.01-1.27)) were statistically associated with a higher SFR compared to RIRS. The pooled mean hospital stays were 1.56 days (95% CI 0.93-2.19) for RIRS, 2.96 days (95% CI 1.78-4.14) for Mini-PCNL, 3.9 days (95% CI 2.9-4.83) for standard PCNL, and 3.66 (95% CI 1.13-6.2) for staged URS. Mini-PCNL and standard PCNL were the most effective treatment options with significant morbidity and length of hospital stay, while RIRS was the safest management option with acceptable SFR, low morbidity, and short hospital stay.
尿石症是最常见的良性泌尿科健康问题。它在全球范围内导致了相当大的发病率、残疾和医疗保健支出负担。对于大肾结石的治疗选择,疗效和安全性的高水平证据有限。这项网络荟萃分析研究了各种大肾结石管理策略的疗效和安全性。采用系统评价和网络荟萃分析(NMA)研究设计,总结了诊断为肾结石大于或等于 2cm 的人类比较随机对照试验。我们的搜索策略基于人群、干预、比较、结局和研究(PICOS)方法。从成立到 2023 年 3 月,我们通过 Medline 中的 PubMed、Embase、Google Scholar、SCOPUS、Science Direct、Cochrane 图书馆、Web of Science 和 ClinicalTrials.gov 进行了搜索,以查找合格的文章。数据提取、筛选、选择和偏倚风险评估由两名独立审查员进行。我们发现了 10 项随机对照试验,共涉及 2917 名患者,其中 9 项被标记为低风险,1 项为高风险。这项网络荟萃分析发现,Mini-PCNL 的 SFR 为 86%(95%CI 84-88%),标准 PCNL 为 86%(95%CI 84-88%),RIRS 为 79%(95%CI:73-86%),分阶段输尿管镜取石术(URS)为 67%(95%CI:49-81%)。标准 PCNL 的总体并发症发生率为 32%(95%CI 27-38%),Mini-PCNL 为 16%(95%CI 12-21%),RIRS 为 11%(95%CI 7-16%)。Mini-PCNL(RR=1.14(95%CI 1.01-1.27)和 PCNL(RR=1.13(95%CI 1.01-1.27))与 RIRS 相比,SFR 更高。RIRS 的平均住院时间为 1.56 天(95%CI 0.93-2.19),Mini-PCNL 为 2.96 天(95%CI 1.78-4.14),标准 PCNL 为 3.9 天(95%CI 2.9-4.83),分阶段 URS 为 3.66 天(95%CI 1.13-6.2)。Mini-PCNL 和标准 PCNL 是最有效的治疗选择,具有显著的发病率和住院时间,但 RIRS 是最安全的管理选择,具有可接受的 SFR、低发病率和短住院时间。